UNSPSC 51171602: Docusate calcium

This classification denotes a stool softener, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F05Q2T2JA0. European Medicines Agency schedules Docusate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06348MIG. Docusate sodium generally arises in the molecular formula C20H37NAO7S. The term 'docusate sodium' is an International Nomenclature of Cosmetic Ingredients designation. As of Q4 2014, DOCUSATE CALCIUM remains the US FDA Preferred Term for this commodity.

Docusate calcium bears US NLM identifiers UMLS ID C0282140 and NCI Concept Code C28999. SMILES: S(=O)(=O)(O)C(CC(=O)OCC(CCCC)CC)C(=O)OCC(CCCC)CC.[NA].

UNSPSC 51171602 Docusate calcium is a Commodity code for a specific stool softener pharmaceutical product that state and local governments procure primarily through multi-jurisdictional cooperative purchasing agreements and institutional health-service contracts rather than direct consumer acquisitions. The recent opportunities on record show state and local issuers buying pharmaceutical products and pharmacy services where docusate calcium appears as one line item among broad generic medication portfolios or as an ancillary pharmaceutical support within clinical operations — most prominently through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceutical contracts and through Texas Health and Human Services Commission pharmacy benefit program development. The mix of issuing bodies includes state health agencies, state purchasing offices administering multi-state cooperative vehicles, and county government departments running clinical or correctional health operations. State procurement offices use cooperative purchasing agreements as the primary vehicle to aggregate demand and negotiate manufacturer pricing across multiple jurisdictions, while institutional buyers (such as county community supervision departments running drug testing operations) source pharmaceuticals as part of broader service contracts where medication supply is ancillary to the primary service mission.

Geographic activity concentrates in Texas and Minnesota, with evidence of multi-state cooperative participation reaching Oregon and other states through MMCAP's framework. The Minnesota Department of Administration's MMCAP issued a Request for Proposal (RFP) for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring vendor compliance with cGMP, DSCSA, and supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with award effective July 1, 2026. The Texas Health and Human Services Commission posted a Request for Information (RFI) on March 27, 2026 to explore direct-to-manufacturer prescription programs and vendor capabilities for implementing pharmacy benefit initiatives, signaling future formal solicitation once the state defines procurement specifications and pricing models. Collin County, Texas is soliciting specimen collection and drug testing services under RFP 2026-327 (due July 23, 2026) where pharmaceutical testing and ancillary medications would be embedded within the selected vendor's service delivery to approximately 25,031 annual tests. The code shows modest but recurring activity within cooperative purchasing frameworks and institutional service contracts rather than standalone pharmaceutical procurement.